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Background: Although the host gene expression in the context of HIV has been explored by several studies, it
remains unclear how HIV is able to manipulate and subvert host gene machinery before and after highly active
antiretroviral therapy (HAART) in the same individual. In order to define the underlying pharmaco-genomic basis
of HIV control during HAART and genomic basis of immune deterioration prior to HAART initiation, we performed
a genome-wide expression analysis using primary peripheral blood mononuclear cells (PBMC) derived from 14
HIV + subjects pre-highly active antiretroviral therapy (HAART) (time point-1 or TP1) with detectable plasma viremia
and post-HAART (time point-2 or TP2) with effective control of plasma viremia (<40 HIV RNA copies/mL of plasma).
Methods: Genomic RNA extracted from the PBMCs was used in microarray analysis using HT-12V3 Illumina chips.
Illumina®BeadStudio Software was used to obtain differentially expressed (DE) genes. Only the genes with p value <0.01
and FDR of <5% were considered for analysis. Pathway analysis was performed in MetaCore™ to derive functional
annotations. Functionally significant genes were validated by qRT-PCR.
Results: Between TP1 and TP2, 234 genes were differentially expressed (DE). During viremic phase (TP1), there was an
orchestrated and coordinated up-regulation of immune, inflammation and antiviral genes, consistent with HIV infection
and immune activation, which comprised of genes mainly involved in antiviral action of interferons and their signalling.
In contrast, the therapy-mediated control phase (TP2) showed systematic down-regulation of these pathways, suggesting
that the reduction in plasma viremia with HAART has a considerable influence on reducing the immune activation,
thereby implying a definitive role of HIV in subverting the human gene machinery.
Conclusions: This is the first study to show the evidence for the differential regulation of gene expression between the
untreated and treated time points, suggesting that gene expression is a consequence of cellular activation during plasma
viremia. Affirmation to these observations comes from down-modulation of genes involved in cellular activation and
inflammation upon initiation of HAART coinciding with below detectable levels of plasma viremia.* Correspondence: nitin.saksena@bigpond.com
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The natural history of HIV is tightly governed by the
plasma viral load and T cell modulation in the absence of
HAART, which results in massive destruction of CD4+ T
cells by multiple mechanisms, leading to T cell exhaustion.
HAART leads to dramatic decrease in HIV RNA levels
and aids in reducing incidence of opportunistic infections
and co-morbidities, mortality rates and stopping second-
ary transmission [1,2].
It is apparent that HIV not only targets CD4+ T cells, but
also has the ability to infect a variety of blood leukocytes
[1,3-5]. This shows that HIV has the inherent ability to
subvert and manipulate the host gene machinery at the
transcriptomic level [6-8], thereby having considerable in-
fluence on the cell morphology, gene expression, and me-
tabolism. Increased gene expression changes have also been
associated with increased viral loads in viremic patients.
Nonetheless the global effects of viral infection on host cell
gene expression patterns pre- and post- antiretroviral ther-
apy in HIV + patients, still remain poorly understood [9].
Recently, the high-density genome-wide microarrays have
greatly facilitated the understanding of genomic basis of
host-pathogen and pharmaco-genomic interactions [9,10].
Following the introduction of HAART, most HIV + pa-
tients who adhere to treatment show a good response, de-
fined by a decrease of plasma viral load (pVL) to
undetectable levels and an immunological reconstitution
with a significant increase of CD4+ T cell levels from base-
line values leading to prolonged survival [11]. The im-
mune reconstitution fails under the value of 200 CD4+ T
cells/ml, which is considered as a critical threshold, and
this occurs in 5–27% of patients receiving HAART
[12,13]. In fact, CD4 + T-cell counts persistently <250
cells/ml, or a percentage of CD4+ T cells <17%, has been
considered a sign of poor immune reconstitution [14]. In
our study, all our patients before the start of therapy
showed 300 CD4+ T cells/mL of blood. Therefore, we
hypothesize that successful HAART treatment in re-
sponders can guide us to find pharmaco-genomic basis of
immunological reconstitution and identify key immune
pathways that cooperate during immune reconstitution
upon effective therapy. To better characterize genomic
events occurring in vivo before and after therapy in HIV +
patients, we have used genome-wide analysis using cDNA
microarrays on frozen primary ex-vivo-derived (uncul-
tured) PBMCs from HIV + patients at two times points-
before (being referred to as TP1 - with detectable plasma
viremia) and after the initiation of HAART (being referred
to as TP2 with below-detectable <20 copies HIV RNA/mL
plasma). The TP2 samples were collected after 2-3 years
apart from the initiation of HAART. All patients showed
rise in CD4+ T cell counts upon suppressive HAART and
reduction in plasma viremia to below detectable levels of
HIV RNA and were therefore, termed responders.In the past, studies using paired design on HIV infected
patients (before and after HAART) have shown that sev-
eral genes are differently expressed between the patients.
They also show that the treatment has a limited effect on
gene expression in vivo [15,16]. In this study, we show for
the first time a genome-wide snapshot of transcriptomic
expression demonstrating that the up-regulation of genes
involved in innate and adaptive immunity, inflammation,
apoptosis and antiviral functions were unique to pre-
therapy with detectable plasma viremia, while their down-
regulation coincided with complete suppression of plasma
virus to below detectable levels (<40 copies/ml plasma)
post-HAART. This distinct regulation of host genes pre-
and post-HAART underpins the significant role of genes
involved in immune activation and inflammation in driv-
ing host gene expression during active HIV infection.
Methods
RNA extraction
For the total RNA extraction, from the frozen PBMCs the
cells were first lysed RNA was extracted as per manufac-
turer’s instructions (Qiagen RNeasy purification kit,
Germany). An on-column digestion of DNA during RNA
purification was performed to purify the samples. The
DNase was efficiently removed in subsequent wash steps.
Total RNA quality was assessed and its concentration was
measured using the Agilent RNA 6000 series II Nano kit
(Agilent Technologies, CA, USA) through Agilent 2100
Bioanalzer as per manufacturer’s protocol. All RNA integ-
rity numbers considered suitable for microarray were 7 or
higher for all samples analysed.
Genome-wide microarray
Total RNA was reverse transcribed to synthesize the first
strand of cDNA, followed by a second-strand synthesis.
Double-stranded cDNA was then transcribed and amplified
in vitro to synthesize biotin labelled complementary mRNA
(cRNA). cRNA amplification and labeling with biotin were
performed using Illumina TotalPrep RNA amplification kit
(Ambion, Inc., Austin, USA) with 250 ng total RNA as in-
put material. cRNA yields were quantified with Agilent
Bioanalyzer. Seven hundred and fifty nanogram of cRNA
sample was hybridized on a HumanHT12 V3 Expression
Bead Chip (Illumina, Inc., CA, USA). The chips were stained
with streptavidin-Cye3 conjugate and scanned using an Illu-
mina BeadArray Reader (Illumina, Inc).
Differential gene expression analysis
Preliminary gene expression analysis was first performed
using Bead Studio software version 3, followed by a de-
tailed analysis in BRB Array Tools. Data was normalized
with cubic spline function in order to minimize variation
due to non-biological factors. The average signal inten-
sity for each gene was measured using Beadstudio v3.
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expression analysis with detection P-value less than
0.01 [17].
Following normalization of the entire chip data, which
covered more than 25,000 annotated human genes and
more than 48,000 probes covering RefSeq and UniGene
annotated genes, we performed clustering analysis in
BRB-Array Tools software. The statistical significance
test used by the BRB-Array software on the 234 DE
genes was Pearson’s centred correlation and the average
linkage method was implemented to obtain the Figure 1.
The data acquired from the Illumina Microarray Bead-
Chip, was further used for obtaining the DE list in Illu-
mina®BeadStudio Data Analysis Software. Further, this
DE gene list was analysed using the BRB-ArrayTools
software installed as an Excel package in order to per-
form a variety of pre-processing steps including comput-
ing probe-set expression summaries, normalization,
filtering and calculating quality control indices [18-20].
Quantile normalization was performed to diminish the
biological errors due to false positives, to see more
clearly the systematic biological differences between the
samples and to compensate for systematic technical dif-
ferences between chips. On the BRB-Array Tools soft-
ware, the Significance Analysis of Microarrays (SAM)
was also performed to identify the genes with statistically
significant changes in expression by assimilating a set of
gene-specific t-tests. During this process, each gene is
assigned a score on the basis of its change in gene ex-
pression relative to the standard deviation of repeated
measurements for that gene. Genes with scores greater
than a threshold are deemed potentially significant. The
percentage of such genes identified by chance is the false
discovery rate (FDR). To estimate the FDR, nonsense
genes were identified by analysing permutations of theFigure 1 Clustering analysis of global gene expression profiles in PBM
study. Similarities in the gene expression patterns among individuals were
correlation and the X-axis shows the time points of each patient. The algor
correlation using a 1-r distance measure. The distance on the X axis represmeasurements. The thresholds were adjusted to identify
smaller or larger sets of genes, and FDRs were calculated
for each set [21]. In this part of the study we used a FDR
of <0.05 with p-value of <0.01 and -1.10 ≤ fold change ≥
2.85, so the genes that received a fold-change value
higher or equal to -1.10 were appointed down-regulated
and the genes that received a fold-change minor or
equal than 2.85 were up-regulated. The cut off for the
fold change was just a consequence of the selection of
FDR and p-value.
Further, the differentially expressed genes between TP1
and TP2 were identified using MeV (MultiExperiment
Viewer) a desktop application for the analysis, visualization
and data-mining of large-scale genomic data. We used false
discovery rate, which defined the expected proportion of
false positives among the declared significant results. FDR
of 5% was used for the differential gene expression analysis
of TP1 and TP2, while using significance analysis of micro-
array (SAM) in order to identify the significant genes for
this group. The differential expressed genes were analysed
as paired samples.
Pathways enrichment analysis
We used the commercial software MetaCore™ (GeneGo,
MI, USA). The differentially expressed genes from
the MeV analysis were further analysed to identify the
biological networks using the GeneGo Maps modules
and GeneGo Folders of the program. Metacore™ con-
ducts functional analysis in the form of network path-
ways based on a manually curated database of human
protein–protein, protein–DNA and protein–compound
interactions, metabolic and signalling pathways and the
effects of bioactive molecules on gene expression. From
each group we selected the most significant pathways. A
p-Value is calculated for the common and uniqueC at time points TP1 and TP2 of the patients enrolled in the
evaluated and visualized with BRB ArrayTools. The Y-axis shows the
ithm used is named Correlation, which computes the Pearson
ents the similarity relationships among samples.
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default the most significant results for the common part
is displayed [22].
To further verify these findings, we further carried out
gene enrichment analysis that consisted of mapping gene
IDs of the dataset onto gene IDs in entities of built-in
functional ontologies represented in MetaCore by path-
way maps and networks. The DE list provided by MeV,
was uploaded in the website of MetaCore™ from
Thomson Reuters Systems Biology Solutions in order to
compare our samples and learn what genes are overrep-
resented in functionally relevant pathways. This analysis
assessed the overall functional character of the sample
set, providing a ranked representation of ontologies that
are most saturated or “enriched” with the input data.
Each GeneGo Process Network represents a comprehen-
sive biological process with a specific functional theme.Quantitative real time PCR (q-RTPCR)
RT-qPCR was used to corroborate the relationship be-
tween expression trends between microarray and RT-
qPCR. 14 genes were selected to be used in RT-qPCR
due to their high observed-score and relevance to this
study. 5ng of total RNA was reverse transcribed using
oligo d(T) and Superscript III followed by RNase H
treatment (Invitrogen Life Technologies), according
manufacture’s protocol. PCR primers were designed for
the genes selected on the basis of the microarray data as
well as for the control genes (GAPDH: Glyceraldehyde
3-phosphate dehydrogenase) using Primer 3 (http://
frodo.wi.mit.edu/primer3/). The cDNA was subjected to
RT-PCR with defined primers and SYBR Green (Invitro-
gen Life Technologies) using MX3000p Stratagene real-
time cycler (Stratagene, La Jolla, CA, USA). The data
were analysed using the MxPro™ QPCR software version
4.0.1 (Stratagene, La Jolla, CA, USA). For all the experi-
ments duplicates were used and relative mRNA expres-
sion was calculated by the comparative ΔΔCt method
for all data. Values of fold changes represent averages
from duplicates experiments. The data were further ana-
lysed by Wilcox test to check the statistical significance.Results
Clinical profiles of patients enrolled in the study
The age range, CD4+ and CD8+ T cell counts, plasma
viral load and HAART regimen that each patient received
are shown in Table 1. All the patients enrolled in this
study were used for blood collection at two time points,
pre- and post-HAART. The separation between time
points is shown in each case in Table 1. As it can also be
seen from Table 1, all our patients responded to treatment
post-HAART coinciding with the rise in CD4+ T cell
counts. Thus, these patients were classed as responders, asthey all achieved below-detectable plasma viremia post-
HAART (<40 copies of HIV RNA/mL plasma).
Hierarchical clustering analysis of the DE genes
We showed in Figure 1, the groups TP1 and TP2 sepa-
rated into two clusters (TP1 = patients before treatment;
TP2 = patients after treatment), clearly showing genomic
distinction between TP1 and TP2 based on the differen-
tially expressed gene list. This gave the confidence to the
dataset to further derive specific DE list between TP1
and TP2 for downstream analysis.
Differential expression analysis of genes between TP1
and TP2
The final list of DE genes for the comparison between
TP1 (pre-therapy) and TP2 (post-therapy) contained 234
genes of which 212 DE genes were down-regulated and
22 up-regulated (see Additional file 1 for the DE genes
list), suggesting significant separable differential expres-
sion between these two time points. This difference seg-
regating the two biological entities between pre-and
post-therapy time points, based on 234 DE genes, was
considered confident enough for downstream pathway,
gene networks and gene enrichment analysis.
Further, the MultiExperiment Viewer (MeV) was then
used to address the differences in analysis requirements
between this data type and traditional gene expression
data. Its tools include automatic conversion functions
from raw count data to processed values and differential
expression detection and functional annotation enrich-
ment detection based on published methods [17]. Using a
website called CIMminer, which generates color-coded
Clustered Image Maps (CIMs) (“heat maps”) to represent
“high-dimensional” data sets such as gene expression pro-
files, we derived a heat map (Figure 2), which confirmed
the differential expression of genes between two groups;
showing strong segregation between TP1 and TP2 based
on the DE genes.
Pathway enrichment analysis
Pathway map prediction reveals dysregulation of intrinsic
Immune response pathways during HIV-1 infection
Following a clear segregation between TP1 and TP2, next
we analysed the functional importance of the DE gene list
at the pathway level in order to derive functionally anno-
tated genes relevant to TP1 and TP2. Genetic pathway
map folders were evaluated using the MetaCore Analytical
Suite (GeneGo Inc) (see Additional file 2 for legend of the
pathways). The aim of this analysis was to determine what
effect virus has on the immune system (seen in TP1) and
how antiretroviral drugs ease the heightened gene expres-
sion, when virus is suppressed to below detectable levels
with therapy in TP2 (see Additional file 1 for the genes in-
volved in the pathways).
Table 1 Clinical profiles showing age, CD4+, CD8+ T cell counts, plasma viral load and the HAART regimen of patients
enrolled in the study
Patients Age Time point CD4 count (cell/μl) CD8 count (cell/μl) Viral load (COPIES/ML) Drugs used during treatment
SC18 27 20/08/96 510-pre 980 112,000 RTV
2 years 07/09/98 710-post 840 < 20 SQV
d4T
3TC
SC19 36 day 3 19/09/96 610-pre 1408 108634 SQV
3 years 08/09/99 720-pos 720 < 20 d4T
3TC
SC 27 33 21/12/96 620-pre 1810 169841 SQV
1.5 years 06/07/98 620-post 1200 < 20 d4T
3TC
SC35 34 19/02/97 750-pre 1380 605236 RTV
2 years 23/03/99 1010-post 840 < 20 SQV
d4T
3TC
SC39 43 04/04/97 n/a n/a 1602 RTV
3 years 05/04/00 < 20 SQV
d4T
3TC
SC40 34 SC peak 18/04/97 600-pre 400 3678 NVP
on + off Rx 16/03/99 800-post 840 < 20 d4T
3TC
SC51 35 pre 28/10/97 400-pre 680 10117 RTV
1 year 28/10/98 810-post 1130 < 20 IDV
d4T
3TC
SC61 25 30/03/98 510-pre 930 6264 RTV
2 years 11/05/00 990-post 870 < 20 IDV
d4T
3TC
SC65 26 20/05/98 360-pre 1380 647095 RTV
2 years 10/05/00 620-post 1217 < 20 IDV
d4T
3TC
SC70 29 16/07/98 650-pre 1069 334088 RTV
3 years 23/04/01 1222post 624 < 20 IDV
d4T
3TC
SC71 31 05/08/98 830-pre 1050 5208 RTV
2 years 13/12/00 1073post 1073 <20 IDV
d4T
3TC
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Table 1 Clinical profiles showing age, CD4+, CD8+ T cell counts, plasma viral load and the HAART regimen of patients
enrolled in the study (Continued)
SC75 34 14/09/98 300-pre 1420 92000 RTV
1 year 23/09/99 610-post 861 < 20 IDV
d4T
3TC
SC64 28 14/05/98 1050pre 950 24835 NEV
2 years 21/03/00 1160post 1106 <20 ddI
d4T
3TC
DT 73 32 13/05/98 510-pre 831 142900 RTV
3 year 26/09/00 722-post 399 < 20 IDV
d4T
3TC
Individual drug abbreviations of the prescribed anti-HIV drugs: 3TC (lamivudine); d4T (stavudine); ddI (didanosine); RTV (ritonavir); SQV (saquinavir); NVP (nevira-
pine); IDV (indinavir); NLF (nelfinavir); NEV (nevirapine). Patients stayed on treatment for 2-3 years in average.
Two time points were used, indicated as pre- and post-therapy in the genome-wide analysis.
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was performed in order to define the functional distribu-
tion of DE genes using MetaCore. Through these analyses,
32 pathway map folders were detected (see Additional
file 3). Among the top 10 overrepresented and statistically
significant pathway map folders belonged to Immune sys-
tem response (20%) (p value 2.824e-7), followed by cell
cycle (p value 3.224e-6), and Inflammatory response
(p value 3.794e-6) (each 17%) Vascular development (12%)
(p value 1.478e-4), Tissue remodelling (8%) (p value
1.882e-4), Apoptosis (p value 2.491e-3), mitogenic signal-
ling (6%) (p value 1.015e-2) and Transcriptional regulation
(5%) (p value1.137e-2), respectively (Figure 3).
Further, we used the MetaCore package to analyze the
differentially expressed genes included in Table 1. A 5% FDR
(p value < 0.01) analysis produced 50 pathway maps (see
Additional file 4 for the full list of pathway maps). Of these,
the top 10 gene maps are summarized in Figure 4 and
Table 2 and assembled according to and in the order of their
significance. As seen in the Pie Chart distribution, the im-
mune response system was the top ranked category, the
pathway enrichment concurred with the map folders and we
obtained 8 of top 10 significantly enriched pathways between
TP1 and TP2 predominantly in the immune response cat-
egory (Figure 4) supported by strong p values (Table 2). This
immune response category comprised of antiviral actions of
Interferons and their signalling, stress-induced antiviral res-
ponse, dendritic cell maturation and migration, TLR signal-
ling and metabolism. Two additional maps that were also
significant were Transcriptional Regulation of cellular metab-
olism and Development of PEDF signalling. It is apparent
from the data shown in Table 3 and Figure 4 that of all im-
mune responses, the involvement and up-regulation of
interferon-related genes and genes related to inflammationpredominated TP1-the time point before the initiation
of HAART followed by their down-regulation following
HAART.Scoring and prioritization of networks/pathways according
to the relevance to input data
Next, we analysed the DE genes in MetaCore networks
in order to address the issue of how different networks
and pathway modules in MetaCore can be prioritized
based on their statistical significance (Figure 5a-e) with
respect to our experimental datasets. Significance was
evaluated based on the size of the intersection between
user’s dataset and set of genes/proteins corresponding to
a network module/pathway in question.
The resulting networks, if significant, will mean that the
algorithm have succeeded in creating modules that have
higher than random saturation with the genes of interest,
which was the case with our dataset shown in Figure 5(b)
under process networks. As can be seen in Figure 6, that of
the top 10 process networks, 5 belonged to inflammation
(all enriched in interferon signalling) and immune response
to virus infection, whereas other 5 were in the develop-
ment, cell adhesion and cell-proliferation. Thus, the top
ranked network was again in inflammation of Interferon
signalling, which again concurs with the pathway analysis
shown in Figure 4.
Further, the examination of disease by biomarker folder
was also consistent with top 3 maps related to RNA virus
infection, which was again consistent with the GO pro-
cesses (Figure 5e) with the top 2 maps in the defence re-
sponse and response to virus. Thus, the process networks,
disease by biomarkers and GO processes were all in con-
cordance with the DE genes relevant to immune response
Figure 2 Heatmap comparison of gene modulation between
TP1 and TP2 groups. This is a graphical representation of the data
(234 DE genes), where the individual values contained in a matrix
are represented as colors: Red means up-regulation and
Green down-regulation.
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to HIV infection.
The Figure 6 shows the ten most enriched GeneGo
processes for the sample set as by their p value. 8 of 10
enrichments, which fully represent only the DE genes
between TP1 and TP2, were in the inflammation/signal-
ling and immune response. A number of these DE genes
are overlapping between the networks as most of them
are involved in the immune system response and inflam-
mation. The representation of all significant genes in the
top ranked 5 pathways is shown in Figure 7a-e.
Another significant and the most notable feature in our
analyses was the predominance and up-regulation of genes
related to immune response and inflammation in TP1,
which was also concordant with the map folders, process
networks and GO processes (Figure 5). The visualization
of GO process network shown in Table 4 showed that the
functional annotation of our DE genes in defense response
(the top ranked category), comprised of genes related to
interferon, interferon-induced or interferon-associated (in-
volved in innate immune response, defense response,
regulation of innate immune and defense response, surface
receptor signalling, cytokine-mediated pathways, etc) and
were highly up-regulated in TP1 when compared to TP2
supported by strong statistical support (Table 3). In these
top 5 pathways, 28 of our DE genes (Table 4) were related
to interferons, antiviral function, interferon signalling,
interferon-induced genes and immune-response/activation
genes with high statistical significance. Thus, the immune
and inflammatory systems with possible involvement of
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Figure 3 Representation of the Top 10 GeneGo Pathway Maps
from Metacore. Significant pathways are represented in the form of
a pie chart where each part represents -log10 of the P-value of that
pathway from the set of over represented pathways, where the total
of these -log10 p values is 1. The p values were determined by
Metacore Pathway analysis based on the chi-squared value for the
expected compared with observed number of genes identified from
that pathway.
Figure 4 Top 10 significantly enriched pathways derived through comparison of DE genes between time point 1 (TP1) and time-point
2 (TP2) of the same patients before and after treatment (FDR < 0.05).
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significant in this comparison (Table 3).
Thus, these analyses unambiguously confirm the involve-
ment and up-regulation of genes involved in the immune
response and inflammation being the most significant driv-
ing force during the viremic (TP1) phase, which could be
largely attributed to immune activation during viremic state
(TP1). Most notable was the regulation in TP2, character-
ized by systematic down-modulation of the very genes,
which predominated TP1. This clearly demonstrates that
HIV not only plays a significant role in subverting the host
gene machinery, but the gene expression is possibly theTable 2 MetaCore Map Folders and Pathways identified in th
Map folder ╟p-value †Ratio
Immune system response 2.824e-7 21/1000 Immune
Cell cycle and its regulation 3.224e-6 14/516
Inflammatory response 3.794e-6 17/775 Immun
Vascular development (Angiogenesis) 1.478e-4 12/543
Tissue remodeling and wound repair 1.882e-4 12/557 Ce
Apoptosis 2.491e-3 14/953
Mitogenic signaling 1.015e-2 9/562
Transcription regulation 1.137e-2 3/71 Apoptosis an
Cell differentiation 1.656e-2 12/940 S
Hypoxia response regulation 3.269e-2 2\43 Development
╟p-value provided by MetaCore™ from GeneGo, Inc. Pathway analysis; † ratio mean
of genes comprising the pathway; IFN (Interferons); PEDF, (Pigment epithelium-derive
to Mesenchymal Transition); EPO (Erythropoietin); PI3K, (Phosphoinositide 3-kinase);
p-values and ratios of differentially expressed genes are shown.main driver of immune activation, which became evident
from the reduction in plasma viremia to below detectable
levels (<40 copies/ml) upon the initiation of HAART treat-
ment, leading to down-modulation of the very genes that
underlie viremia and immune activation.
Quantitative real time PCR corroboration of 14 DE genes
Following the microarray analysis, quantitative real-time
PCR (qRT-PCR) was performed using the same RNA
samples in order to functionally validate expression pat-
terns of some of the functionally, but statistically signifi-
cant genes between microarray and qRT-PCR. Wee comparison between TP1 and TP2 (p < 0.01, FDR < 0.05)
Pathway maps ╟p-value †Ratio
response_IFN alpha/beta signaling pathway 8.104e-5 5\24
Development_PEDF signaling 2.255e-2 6\53
e response_HMGB1/TLR signaling pathway 6.734e-4 5\36
Development_PEDF signaling 1.689e-2 4\49
ll adhesion_Cell-matrix glycoconjugates 4.201e-2 3\38
Development_PEDF signaling 4.224e-3 4\49
Development_PEDF signaling 4.656e-3 4\49
d survival_Role of PKR in stress-induced apoptosis 4.099e-1 3\53
ome pathways of EMT in cancer cells 2.340e-2 3\51
_EPO-induced PI3K/AKT pathway and Ca(2+) influx 1.000e + 0 2\43
ing the number of differentially regulated pathway genes versus total number
d factor); HMGB1 (High mobility group 1); PKR, (Protein kinase R);EMT (Epithelial
AKT, (Protein Kinase B); Ca (Calcium).
Table 3 Generation of biological networks by MetaCore™ for the defense response for the disease section of the
enrichment analysis
Key network objects GO processes p-Value
AKT(PKB), Caspase-9, HMGB1, Bcl-XL, IKK-beta Regulation of defense response (74.0%), regulation of response to
stress (80.0%), regulation of immune system process (82.0%),
regulation of response to stimulus (92.0%), toll-like receptor 1
signaling pathway (40.0%)
1.31e-16
ATM, p21, MLL/MEN fusion protein, E1B-AP5, HEXIM1 Regulation of cell cycle (38.0%), cell cycle checkpoint (24.0%),
chromatin organization (30.0%), negative regulation of cellular
process (60.0%), chromatin modification (28.0%)
4.22e-39
CD19, CD79 complex, MHC class II, CD79B, IL-8 Immune response-regulating cell surface receptor signaling pathway
(53.1%), positive regulation of T cell activation (55.1%), T cell
co-stimulation (44.9%), lymphocyte co-stimulation (44.9%),
response to interferon-gamma (49.0%)
1.82e-32
G3BP1 (hdhVIII), H-Ras, GPIAP1, ACSL3, IFNAR2 Leukocyte migration (46.0%), cell activation (54.0%), cell migration
(52.0%), hemostasis (48.0%), localization of cell (52.0%)
2.05e-29
Casein kinase II, alpha chains, CD4, HSP27, IRF4, HDAC6 Regulation of macromolecule metabolic process (87.8%), regulation
of primary metabolic process (87.8%), developmental process (87.8%),
regulation of cellular metabolic process (87.8%), regulation of cellular
biosynthetic process (79.6%)
1.40e-29
This is a variant of the shortest paths algorithm with main parameters of relative enrichment with the uploaded data and relative saturation of networks with
canonical pathways. These networks are built on the fly and unique to the uploaded data. In this workflow the networks were prioritized based on the number of
fragments of canonical pathways on the network.
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IFNB, IFNG, IL6, IL1Beta, IRF7, IRF9, OAS1 to 3, PKR
and TLR-7) shown in Figure 8, which were directly or
indirectly related to interferon function, signalling and
immune response. All 14 DE genes showed consistentFigure 5 Enrichment in functional ontologies for the comparison betw
across five ontologies in MetaCore: (a) GeneGo pathway maps; (b) GeneGo
(e) GeneGo processes. The associated false discovery rate is less than 0.01 ftrends between qRT-PCR and microarray, implying their
functional relevance (Figure 8).
With the help of GraphPad Prism® a more in-depth
correlation analysis was performed for individual genes
to validate the statistical significance of their expressioneen patients before and after treatment. Enrichment analysis
networks; (c) GeneGo disease by biomarkers (d) GO processes and
or a p-value threshold less than or equal to 0.01.
Figure 6 Process Networks by Enrichment analysis in MetaCore™ software; these are the top 10 process network pathways accordingly
with their p-value calculated by the program.
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tween microarray and RT-qPCR expression trends
(Figure 9). For each of the genes, standard coefficient
correlation and paired t test were performed to show
how the genes expressed between different groups and
also their significance. We identified 13 of 14 genes
showing statistically significant relationship in expres-
sion trends between microarray and RT-qPCR, with
OAS3 being the only exception (Figure 3). Although 13
of 14 genes showed confident R2 values, the genes PKR,
CXCL10, CCL8, IL-6, OAS2, IFNbeta and IFN delta
showing R2 value >0.5 coupled with excellent p values
(Figure 8). Although in RT-qPCR, only 11 of 14 achieved
statistical significance, the three exceptions (PKR, TLR7
and OAS2) (Figure 9) showed perfect correlation in ex-
pression trends between microarray and RT-qPCR.
Discussion
Even though there have been many reports of gene ex-
pression changes at different stages of HIV infection
[23] the information on how genomic modulation occurs
in HIV-infected individuals assessing whole transcrip-
tome before and after HAART therapy and the genomic
basis of the effects of anti-HIV drugs leading to recovery
of genes involved in immune reconstitution is still very
limited [15,16,24].In this study, we have carried out a genome-wide tran-
scriptomic analysis of primary PBMCs derived from 14
HIV + patients before and after the initiation of HAART
therapy to ascertain whether HIV leads to perturbations
in immunity-related genes and if so, how these immune
function-related genes recover from insults incurred by
HIV following HAART when virus becomes below de-
tectable to <20 copies of HIV RNA/ml. These study pa-
tients were classed as responders, which was consistent
with concomitant rise in their CD4+ T cell counts
coupled with reduction in plasma viremia following
HAART. The immune reconstitution fails under the
value of 200 CD4+ T cells/ml, which is considered as a
critical threshold and this occurs in 5–27% of patients
receiving HAART [14,25]. In fact, CD4 +T-cell counts per-
sistently < 250 cells/ml or a percentage of CD4 T cells < 17,
have been considered a sign of poor immune reconstitution
[26]. In our study, all our patients showed CD4+ T cell
counts of 300/uL blood and above. Therefore, we believe
that successful HAART treatment in responders will better
reflect the genomic basis of immunologic reconstitution
and the genes involved in the immune system recovery.
We analysed the peripheral blood mononuclear cells in
order to obtain a global snapshot of the differences in gene
expressions emanating as a consequence of host-virus
interaction. We believe that a single cell type will not be
Figure 7 Canonical pathway maps represent a set of about 650 signalling and metabolic maps covering human biology (signalling
and metabolism) in a comprehensive way. All maps are drawn from scratch by GeneGo annotators and manually curated and edited.
Experimental data is visualized on the maps as blue (for downregulation) and red (upregulation) histograms. The height of the histogram
corresponds to the relative expression value for a particular gene/protein (MetaCore™). a) Immune response_Antiviral actions of Interferons
pathway; b) Immune response_IFN alpha/beta signaling pathway; c) Immune response_Role of PKR in stress induced antiviral cell response;
d) Immune response_HMGB1/TLR signaling pathway; e) Immune response_Role of HMGB1 in dendritic cell maturation and migration.
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differentially expressed genes were detected between pre-
and post-therapy time points, which demonstrate the evi-
dence for distinct transcriptional signatures that segregatedthe pre-therapy (viremic), and post-therapy (aviremic) time
points of HIV + patients. The untreated stage (TP1) was
characterized by up-regulation of genes that were related to
immune system function, inflammation and activation with
Table 4 Over representation of genes significant in TP1 versus TP2 comparison, based on the top 5 significant
pathways
Gene annotation p-value Cell function Regulation
IFI6 p < = 0.001198 Regulation of apoptosis Down
IFN- β* p < = 0.001647 Antiviral activity which is Mainly involved in innate immune response Down
IFN-γ* p < = 0.008242 Critical for innate and adaptive immunity against Viral and intracellular bacterial
infections and for tumor control
Down
IL-1β* p < = 0.005439 An important mediator of the inflammatory response, and is involved in a variety
of cellular activities, including cell proliferation, differentiation, and apoptosis
Down
IL-6* p < = 0.002616 Acts as both a pro-inflammatory and anti-inflammatory cytokine; stimulate
immune response
Down
IL1RN p < = 0.0007325 Inhibits the activity of IL-1 by binding to its receptor Down
ISG15 p < = 0.0007325 Antiviral activity during viral infections Down
ISG54 p < = 0.0004398 Restrict virus infection through alteration of cellular protein synthesis Down
MIP-α p < = 0.0003696 Involved in the acute inflammatory state in the recruitment and activation
of polymorphonuclear leukocytes
Down
OAS1* p < = 0.002616 Involved in the innate Immune response to viral infection Up
OAS2* p < = 0.004717 Involved in the innate Immune response to viral infection Up
OAS3* p < = 2.622e-05 Involved in the innate Immune response to viral infection Up
PKR* p < = 0.01396 Inhibits further cellular mRNA translation, thereby preventing viral Protein synthesis;
induce cellular apoptosis, to prevent further viral spread
Down
STAT1 p < = 0.002616 Signal transducer and activator of transcription that mediates signaling by interferons Up
STAT2 p < = 0.01797 Signal transducer and activator of transcription that mediates signaling by type I IFNs Up
WARS p < = 0.006259 Catalyzes the aminoacylation of tRNA(trp) with tryptophan and is induced by
interferon; associated with angiogenesis
Up
*Genes that were validated by RT-PCR in this study: IFI6, (Interferon alpha-inducible protein 6); IFN- β, (Interferon beta); IFN-γ (interferon gamma); IL-1β
(Interleukin-1 beta); IL-6, (interleukin 6); IL1RN, (interleukin 1 receptor antagonist); ISG, (interferon stimulated gene); MIP, (Major intrinsic protein of lens fiber);
OAS (2′-5′-oligoadenylate synthetase); PKR, (protein kinase R); WARS, (Tryptophanyl-tRNA synthetase).
The 16 genes shown in the table are from the DE list and were found to be involved across 5 pathways, which were also validated by q-RT PCR.
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response genes encompassing antiviral interferons and their
signalling, DC maturation and migration, IL-1 signalling,
etc. Other 2 pathway maps were related to development
and transcriptional regulation. In contrast, treated stage
(TP2) when below detectable levels of plasma viremia (<20
copies/ml plasma) was achieved with successful HAART,
systematic down-regulation of these functional categories
was observed, suggesting that most of the alterations inFigure 8 qRT-PCR validation of 14 significant DE genes. Correlation of
microarray. Blue colour represents microarray fold change and the red colo
qRT-PCR and microarray across all 14 genes are shown underneath each ggene expression observed in untreated stage resumed
desired functional levels upon the initiation of HAART
treatment. This finding is consistent with the work of
Massanella et al. [24] and Li et al. [15], where they showed
an abatement of innate immune response following treat-
ment. It is important to iterate that post-therapy down-
regulation of immune function related genes, specifically to
interferon antiviral/signalling genes, inflammatory and cel-
lular activation may be indicative of reduction in cellularthe fold change of the 14 selected genes between qRT-PCR and
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Figure 9 (See legend on next page.)
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(See figure on previous page.)
Figure 9 Association of gene expression by real-time PCR of the DE found significant in our analysis. Representative scatterplots with
linear regression analysis confirm the association between expression levels between microarray and q-RTPCR (figures b, d, f, h, j, l, n, p, r, t, v,
y and z) p-values for the expression between the different group were measured using the GraphPad Prism®software and also correlation values
(a, c, e, g, i, k, m, o, q, s, u, x and w). The significant ones were in the range of p < 0.001 and with the R2 value closer to 1.
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therapy and more rapidly in responders- as evidenced here
in this study. This argument becomes even more conceiv-
able when the degree of T cell activation is compared
between two groups. It has been shown that the degree of
T cell activation is lower in controllers than in non-
controllers, but higher than observed in HIV uninfected in-
dividuals and higher than observed in antiretroviral-treated
patients [27]. This corroborates with our observations
showing considerably reduced cellular activation levels
upon successful HAART signalled by systematic down
regulation of the very genes involved in these functional
pathways. Therefore, it is plausible to hypothesize that gene
expression and its modulation pre-therapy is possibly
guided, in part, by cellular activation as a consequence
of HIV infection, whereas the down-regulation of these
functional pathways post-HAART aid immune reconsti-
tution, pointing at possible genomic basis of immune-
reconstitution upon successful HAART. Overall, this
analysis showed an aspect of host gene expression pre-and
post HAART and is consistent with the findings on the role
of HAART treatment in slowing the rate of HIV disease
progression and AIDS with improved patient outcomes [28].
The interferon (IFN) system is a well-studied branch
of the innate immune system active against viruses. The
infection of cells by many viruses provokes synthesis and
secretion of IFNs, which mediates induction of a cellular
antiviral state that obstructs further viral spread. For
HIV, previous studies have implicated IFNs in blocking
both early and late stages of the HIV-1 life cycle [29,30].
Our data not only confirmed these previous studies, but
also are unique in showing molecular signatures, up-
regulation and over-representation of immune response
genes enriched in IFN and IFN-related pathways with
over 25 statistically significant genes during untreated
HIV infection as opposed to the treated stage. A closer
examination of top 5 pathways immune response path-
ways showed that even though considerable numbers of
genes were overlapping between them, they were all
functionally related to IFN family within the immune re-
sponse folder. The top-ranking pathway was antiviral ac-
tion of Interferon, enrichment of over 12 DE genes
(IFN-beta, IFN-gamma, STAT1, STAT2, IRF9, WARS,
PKR, OAS1, OAS2, OAS3, MxA, ADAR1) during un-
treated stage. All these genes have in common is the
activation of the IFN family. It is known that HIV-1
interacts through multiple signalling pathways toreprogram the transcriptome and the proteome of host
cells by subverting the host immune defense and anti-
viral function [31].
The second most significant pathway involved during
the untreated stage was related to signalling of IFN-beta
and gamma, both produced by immune cells. These in-
terferons were also related to antiviral responses and are
implicated in blocking both early and late stages of the
HIV-1 life cycle [32]. Most of the genes overlapped with
the top-ranked pathway and all of these genes were re-
lated to IFN signalling and they were all up-regulated
during the untreated stages of HIV infection.
The third most significant pathway that we show here
was related to HMGB1 and TLR signalling down-
regulated in TP2 (Figure 7d). High mobility group box 1
(HMGB1) is a DNA-binding nuclear protein that can act
as an alarmin, a danger signal to alert the innate im-
mune system for the initiation of host defence [33]. They
recognize distinct pathogen-associated molecular pat-
terns and play a critical role in innate immune responses
[34-36]. The most significant genes in this particular
pathway were Ik-β, MIP1-α, IL-6, IL1RN, IL-1β, IRF7,
IFN-β. Previous studies have shown that Toll-like recep-
tor (TLR) pathway contributes to the persistent immune
activation observed in chronically HIV-1–infected indi-
viduals. Even though the link between immune activa-
tion and HIV-1 disease progression is well established,
the underlying genomic basis through which HIV-1 in-
duces immune activation remains unclear. In our study,
the TLR7 was enriched in the top ranked immune re-
sponse pathway (p < 0.001926). It has been demonstrated
that HIV-1 encodes for multiple TLR7/8 ligands that can
mediate direct activation of the immune system in vitro
[37]. Moreover, evidence for a role of chronic TLR
stimulation in HIV-1 pathogenesis has been recently de-
scribed in a murine model, which showed that chronic
activation of TLR7 can directly lead to immune activa-
tion as well as an array of immune dysfunction similar
to those observed in human HIV-1 chronic infection
[38]. Interestingly, recent data from the non-human pri-
mate model of HIV-1 infection provided additional
support for a role of the TLR7 pathway in HIV-1 patho-
genesis [39]. Apart from this, other genes involved in
immune activation (such as CD38, CD83 and TNFSR
family) were also significantly expressed and were up-
regulated during the untreated phase, suggesting im-
mune activation as one key aspect of the viremic stage
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creased gene expression changes associated with in-
creased plasma viral loads in viremic patients [10].
The most notable aspect of these studies is an unam-
biguous demonstration of up-regulation of the most of
the pathways related to immune response during the un-
treated stage of HIV infection followed by down-
regulation of the same pathways observed during the
HAART-treated stage of HIV infection. By up-regulating
most of the pathways related to the IFN system, the host
cells could be more in control of virus replication which
will determine the course of the infection. It becomes
more conceivable, when we see that the increase of IFN
production is negatively linked to viral loads. Therefore,
it is obvious that the immune activation in patients with-
out HAART treatment affected by the virus is trying to
protect the disease spread, which is a beneficial aspect
aiding the untreated stage. If we compare this scenario
in chronically infected HIV patients, who control virus
in the absence of therapy and have below detectable
HIV, there is an emerging consensus that much of the
inflammatory response related to cellular activation over
time does more harm than good.
What we have shown here is that the virus causes more
profound functional changes by subverting and in ma-
nipulating the host cell gene machinery by regulating the
most important part of the host immune system, thereby
leading to inflammation and immune system activation. In
this context, not only the IFN system pathway and the
immune response pathways were the most significant,
but the high mobility group box 1 (HMB1) was also up-
regulated in patients before treatment, which signals
heightened innate immune responses to virus infection.
This pathway has more profound importance and is re-
lated to the response to exogenous pathogens molecules,
acting as a danger signal and triggering inflammation [28].
That means that the HIV-1 virus regulates all the levels of
the innate immune response including the signalling in-
flammation by up-regulating the genes related to this role
such as STAT-1, MIP-1α, IL-6, IL1RN and IL1β, as seen in
our study. The affirmation to this proof is reflected in the
down-modulation of these very genes upon successful
HAART and below detectable levels of plasma viremia
(TP2) in our study.
Overall, our study is unique not only in demonstrating
how virus subverts the host gene machinery by up-
regulating key immune response and genes involved in
inflammation and cellular activation, but also in showing
that HAART therapy modulates gene expression and
overcomes the insults that are neutralized upon the initi-
ation of HAART therapy. In simple terms, the successful
outcome of HAART therapy can now be visualized gen-
omically through the down-regulation of particular im-
mune and inflammation genes, as this study has shown.It is known that therapy leads to the reconstitution of
the immune system and we show that the down-
regulation of the most important genes related to im-
mune system response and inflammation may provide
respite from cellular activation/inflammation in HIV pa-
tients. HAART treatment can improve clinical, virologic,
and immunologic characteristics, but very little is known
of the host molecular mechanisms underlying untreated
versus HAART treated stage of the same patient. Our
work shows that although there is a common set of key
genes associated with HIV with altered expression in
both stages, each stage (pre-and-post therapy) was char-
acterized by unique molecular signatures, which have
immense clinical significance.
In summary, the results presented in this study offer
new comparative insights related to disease status that
can distinguish differentiated patterns of gene expression
between HIV patients before and after HAART, which
can reveal how genomic insults incurred by HIV recover
following the initiation of HAART. Taken together, the
innovative approach we have used can be applied to dis-
ease conditions other than HIV where correlating com-
plex cellular and molecular signatures of immunity may
provide new insights in the mechanisms of pathogenesis
and success of therapy.Conclusion
Our results demonstrate for the first time a clear genome-
wide distinction between HIV patients pre-and post highly
active antiretroviral therapy. They clearly show that im-
mune activation and inflammation play a significant role
in host gene expression in HIV + individuals with viremia.
Affirmation to these observations came from successful
HAART therapy down-regulating the very genes and
pathways that guided viremia and immune activation. This
is the first study to show key genomic differences pre-and
post-HAART in the same patient, highlighting how virus
subverts the host gene machinery and how antiretroviral
drugs neutralize this effect at the level of host genome,
thereby providing the first snapshot of genomic basis of
immune deterioration during viremia and its reconstitu-
tion upon successful HAART. Many of the genes and
pathways identified in this study will further facilitate the
development of new generation of diagnostic markers and
novel genome-based strategies for therapeutic interven-
tions for HIV patients.Additional files
Additional file 1: Differentially expressed gene list derived through
comparison of genes between TP1 versus TP2 based on their
observed scores. A total of 234 genes were differentially expressed
between TP1 and TP2.
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